Circulating miR-215-5p and miR-642a-5p as potential biomarker for diagnosis of osteosarcoma in Mexican population
Por:
Monterde-Cruz L., Ramírez-Salazar E.G., Rico-Martínez G., Linares-González L.M., Guzmán-González R., Delgado-Cedillo E., Estrada-Villaseñor E., Valdés-Flores M., Velázquez-Cruz R., Hidalgo-Bravo A.
Publicada:
1 ene 2018
Ahead of Print:
1 ene 2018
Resumen:
Osteosarcoma is the most common malignant bone neoplasia affecting individuals in the second decade of life. The survival rate has not been improved during the last 25 years, in part because of the lack of specific markers. The microRNAs have been identified as important regulators of gene expression, experimental evidence suggests these molecules as key players in cancer development and progression. To identify miRNAs differentially expressed in serum from patients with osteosarcoma compared to healthy donors in Mexican population. Fifteen osteosarcoma patients and fifteen age and sex matched healthy individuals were recruited. Two pools of total RNA extracted from serum per study group were prepared and the miRNA expression profiles were analyzed through TaqMan Low Density Arrays. Validation was carried out through RT-qPCR using individual TaqMan assays for those miRNAs differentially expressed. Fifteen miRNAs were differentially expressed in osteosarcoma patients compared to healthy controls. Overexpression of miR-215-5p and miR-642a-5p was confirmed by validation through RT-qPCR. The expression analysis of miRNAs from serum in osteosarcoma patients revealed differential expression of miR-215-5p and miR-642a-5p. Both microRNAs are potential markers for osteosarcoma diagnosis. © 2018, Japan Human Cell Society and Springer Japan KK, part of Springer Nature.
Filiaciones:
Monterde-Cruz L.:
Department of Genetics, National Institute of Rehabilitation, Calzada Mexico-Xochimilco 289, Arenal de Guadalupe, Mexico City, Mexico
Ramírez-Salazar E.G.:
Genomics of Bone Metabolism Laboratory, National Institute of Genomic Medicine (INMEGEN), Periferico Sur 4809, Arenal Tepepan, Mexico City, Mexico
CONACYT-National Institute of Genomic Medicine (INMEGEN), Periferico Sur 4809, Arenal Tepepan, Mexico City, Mexico
Rico-Martínez G.:
Department of Genetics, National Institute of Rehabilitation, Calzada Mexico-Xochimilco 289, Arenal de Guadalupe, Mexico City, Mexico
Linares-González L.M.:
Department of Genetics, National Institute of Rehabilitation, Calzada Mexico-Xochimilco 289, Arenal de Guadalupe, Mexico City, Mexico
Guzmán-González R.:
Department of Genetics, National Institute of Rehabilitation, Calzada Mexico-Xochimilco 289, Arenal de Guadalupe, Mexico City, Mexico
Delgado-Cedillo E.:
Department of Genetics, National Institute of Rehabilitation, Calzada Mexico-Xochimilco 289, Arenal de Guadalupe, Mexico City, Mexico
Estrada-Villaseñor E.:
Department of Genetics, National Institute of Rehabilitation, Calzada Mexico-Xochimilco 289, Arenal de Guadalupe, Mexico City, Mexico
Valdés-Flores M.:
Department of Genetics, National Institute of Rehabilitation, Calzada Mexico-Xochimilco 289, Arenal de Guadalupe, Mexico City, Mexico
Velázquez-Cruz R.:
Genomics of Bone Metabolism Laboratory, National Institute of Genomic Medicine (INMEGEN), Periferico Sur 4809, Arenal Tepepan, Mexico City, Mexico
Hidalgo-Bravo A.:
Department of Genetics, National Institute of Rehabilitation, Calzada Mexico-Xochimilco 289, Arenal de Guadalupe, Mexico City, Mexico
|